Key clinical point: Daily aspirin use was associated with a significantly lower risk for new-onset and advanced fibrosis.
Major finding: Daily aspirin users had significantly lower risk for developing incident advanced fibrosis compared with nonregular users (adjusted hazard ratio, 0.63; 95% CI, 0.43-0.85).
Study details: Prospective cohort study of 361 adults with biopsy-confirmed nonalcoholic fatty liver disease.
Disclosures: Funders included the National Institutes of Health and the AASLD Foundation. The investigators reported having no conflicts of interest.
Simon TG et al. Clin Gastroenterol Hepatol. 2019 May 8.